Advancing acute myeloid leukemia immunotherapy: transcriptomic profiling-guided donor selection combined with an innovative natural killer cell expansion protocol
Gene signatures now help doctors select the most effective natural killer cells for each patient, while better preservation keeps cells potent longer.
This study develops a transcriptomic-based donor selection approach for NK cell immunotherapy in AML, identifying gene signatures that predict superior cytotoxicity. A novel GMP-compliant expansion protocol with intermediate cryopreservation maintains cell quality and improves therapeutic timing.
What the study was
- Study design
- Experimental (in vitro donor selection + expansion protocol)
- Population
- NK cell donors for AML immunotherapy
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cytotherapy
Why it surfaced
Practical innovation for NK cell therapy manufacturing with transcriptomic donor selection. In vitro only but GMP-compliant.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.